University of Alabama at Birmingham
uab.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,388
Active
359
Phase 3
53
Total enrollment
1,214,551
Pipeline matrix
Showing 40 of 151 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Metformin | — | — | — | — | 2 | ||
| Amoxicillin | — | — | — | — | 2 | ||
| Buprenorphine | — | — | — | — | — | 2 | |
| Benzathine Penicillin | — | — | — | — | — | 1 | |
| Bodewell Calming Cream | — | — | — | — | — | 1 | |
| Baricitinib 4 MG Oral | — | — | — | — | — | 1 | |
| Pneumococcal Vaccine | — | — | — | — | — | 1 | |
| Hizentra | — | — | — | — | — | 1 | |
| Methyl Prednisolone | — | — | — | — | — | 1 | |
| Standard Post-Operative Pain Control | — | — | — | — | — | 1 | |
| Surgeon's Standard ACL Postoperative Regimen | — | — | — | — | — | 1 | |
| Caffeine citrate 20mg/kg/day | — | — | — | — | — | 1 | |
| Multiple Product PrEP Program | — | — | — | — | — | 1 | |
| Jynneos | — | — | — | — | — | 1 | |
| Capvaxvie | — | — | — | — | — | 1 | |
| 20-valent pneumococcal conjugate vaccine | — | — | — | — | — | 1 | |
| Flucelvax | — | — | — | — | — | 1 | |
| Fluzone High-Dose | — | — | — | — | — | 1 | |
| Fluad | — | — | — | — | — | 1 | |
| Vevye | — | — | — | — | — | 1 | |
| fluzone | — | — | — | — | 2 | ||
| oral tranexamic acid | — | — | — | — | — | 1 | |
| AZM Group | — | — | — | — | — | 1 | |
| Sacubitril-Valsartan 49 Mg-51 Mg Oral | — | — | — | — | — | 1 | |
| Valsartan 80 mg Oral | — | — | — | — | — | 1 | |
| LTOWB | — | — | — | — | — | 1 | |
| Components | — | — | — | — | — | 1 | |
| Tenofovir Disoproxil Fumarate | — | — | — | — | — | 1 | |
| Lamivudine Oral Solution | — | — | — | — | — | 1 | |
| Insulin Glargine | — | — | — | — | — | 1 | |
| Dorzagliatin | — | — | — | — | — | 1 | |
| targeted synthetic DMARD class | — | — | — | — | — | 1 | |
| non-TNFi-biologic class | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 4 | |
| Carboplatin | — | — | — | — | — | 5 | |
| Bevacizumab | — | — | — | — | 4 | ||
| Pirfenidone | — | — | — | — | — | 2 | |
| M032 | — | — | — | — | 2 | ||
| Dexamethasone | — | — | — | 5 | |||
| rituximab | — | — | — | — | 6 |
111 more active programs hidden
Next readouts
- 2018-12-11
- 2022-09
- 2023-07-31
- 2024-10-25
- 2025-07-29
- 2025-11-21
- 2025-11-30
- 2026-02
- 2026-05-01
- 2026-05-11
Top conditions
- Obesity54
- Hypertension32
- Breast Cancer29
- Stroke23
- HIV23
- Multiple Sclerosis19
- HIV Infections17
- Cystic Fibrosis17
Frequently asked questions about University of Alabama at Birmingham
- How many clinical trials does University of Alabama at Birmingham have on ClinicalTrials.gov?
- University of Alabama at Birmingham is listed as the lead sponsor on 1,388 clinical trials in ClinicalTrials.gov, 359 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Alabama at Birmingham's trials are in Phase 3?
- 53 of University of Alabama at Birmingham's trials are in Phase 3, spread across 151 active drug programs.
- What therapeutic areas does University of Alabama at Birmingham focus on?
- University of Alabama at Birmingham's most-studied conditions on ClinicalTrials.gov are Obesity, Hypertension, Breast Cancer, Stroke, HIV.
- When are University of Alabama at Birmingham's next clinical trial readouts?
- University of Alabama at Birmingham has 10 upcoming primary-completion readouts tracked here; the soonest is “Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors”, expected around 2018-12-11.